Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
Conditions
Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
Trial Timeline
Feb 2, 2026 → May 31, 2026
NCT ID
NCT07465029About Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion is a pre-clinical stage product being developed by Bristol Myers Squibb for Lower-risk Myelodysplastic Syndromes (TD LR-MDS). The current trial status is active. This product is registered under clinical trial identifier NCT07465029. Target conditions include Lower-risk Myelodysplastic Syndromes (TD LR-MDS).
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07465029 | Pre-clinical | Active |
Competing Products
1 competing product in Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| JSP191 | Jasper Therapeutics | Phase 1 | 25 |